The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1259-1266 , December 2009

Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment

Received 13 July 2009 ,Revised 3 September 2009 ,Accepted 8 September 2009.

References 

  1. Ehrlich P. On Immunity with special reference to cell life. Proc R Society. 1899;66:424–433
  2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497
  3. Albrecht H, Radosevich JA, Babich M. Fundamentals of antibody-related therapy and diagnostics. Drugs Today (Barc). 2009;45:199–211
  4. Calogiuri G, Ventura MT, Mason L, Valacca A, Buquicchio R, Cassano N, et al. Hypersensitivity reactions to last generation chimeric, humanized and human recombinant monoclonal antibodies for therapeutic use. Curr Pharm Des. 2008;14:2883–2891
  5. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18:465–471
  6. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26:66–73
  7. Baert F, Noman M, Vermeire S, Van Assche G, G DH, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601–608
  8. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932–1939
  9. Soykan I, Ertan C, Ozden A. Severe anaphylactic reaction to infliximab: report of a case. Am J Gastroenterol. 2000;95:2395–2396
  10. Herceptin prescribing information. Genentech; Revised 3/2009. Available at:http://www.gene.com/gene/products/information/pdf/herceptin-prescribing.pdf. Accessed July 1, 2009
  11. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology. 2001;61(suppl 2):58–66
  12. Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol. 2006;96:624–627
  13. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc. 2007;28:313–319
  14. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910
  15. Baudouin V, Crusiaux A, Haddad E, Schandene L, Goldman M, Loirat C, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation. 2003;76:459–463
  16. Leonard PA, Woodside KJ, Gugliuzza KK, Sur S, Daller JA. Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody. Transplantation. 2002;74:1697–1700
  17. Hawkins C, Gatenby P, McGill D. Severe hypotension complicating primary angioplasty: allergy to abciximab. Allergy. 2003;58:688–689
  18. Pharand C, Palisaitis DA, Hamel D. Potential anaphylactic shock with abciximab readministration. Pharmacotherapy. 2002;22:380–383
  19. O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007;25:3644–3648
  20. Gell PGH, Coombs RRA. Clinical Aspects of Immunology. 1st ed. Oxford (UK): Blackwell; 1963;
  21. Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol. 2006;6:476–481
  22. Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol. 2005;94:575–580
  23. Pruzansky JJ, Patterson R. Desensitization of human basophils with suboptimal concentrations of agonist. Evidence for reversible and irreversible desensitization. Immunology. 1988;65:443–447
  24. Paolini R, Numerof R, Kinet JP. Phosphorylation/dephosphorylation of high-affinity IgE receptors: a mechanism for coupling/uncoupling a large signaling complex. Proc Natl Acad Sci U S A. 1992;89:10733–10737
  25. Rubinchik E, Shalit M, Levi-Schaffer F. Responsiveness of human skin mast cells to repeated activation: an in vitro study. Allergy. 1998;53:14–19
  26. Macglashan D, Miura K. Loss of syk kinase during IgE-mediated stimulation of human basophils. J Allergy Clin Immunol. 2004;114:1317–1324
  27. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122:574–580
  28. Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, et al. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther. 2006;24:851–858
  29. Lelong J, Duburque C, Fournier C, Colombel JF, Desreumaux P, Tonnel AB, et al. Desensitisation to infliximab in patients with Crohn's disease. Rev Mal Respir. 2005;22:239–246
  30. Puchner TC, Kugathasan S, Kelly KJ, Binion DG. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis. 2001;7:34–37
  31. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol. 2005;99:393–399
  32. Melamed J, Stahlman JE. Rapid desensitization and rush immunotherapy to trastuzumab (Herceptin). J Allergy Clin Immunol. 2002;110:813–814
  33. Georgitis JW, Browning MC, Steiner D, Lorentz WB. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. Ann Allergy. 1991;66:343–347
  34. Jerath MR, Kwan M, Kannarkat M, Mirakhur B, Carey L, Valgus J, et al. A desensitization protocol for the mAb cetuximab. J Allergy Clin Immunol. 2009;123:260–262
  35. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114:371–376
  36. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005;96:824–829
  37. Breslow RG, Caiado J, Castells MC. Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol. 2009;102:155–160
  38. Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach JF. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol. 1986;137:830–838
  39. Frodin JE, Lefvert AK, Mellstedt H. The clinical significance of HAMA in patients treated with mouse monoclonal antibodies. Cell Biophys. 1992;21:153–165
  40. Legouffe E, Liautard J, Gaillard JP, Rossi JF, Wijdenes J, Bataille R, et al. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin Exp Immunol. 1994;98:323–329
  41. Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood. 2002;99:2054–2059
  42. Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999;17:791–795
  43. Castells M. Mast cell mediators in allergic inflammation and mastocytosis. Immunol Allergy Clin North Am. 2006;26:465–485
  44. Bush RK, Wood RA, Eggleston PA. Laboratory animal allergy. J Allergy Clin Immunol. 1998;102:99–112
  45. Matsui EC, Simons E, Rand C, Butz A, Buckley TJ, Breysse P, et al. Airborne mouse allergen in the homes of inner-city children with asthma. J Allergy Clin Immunol. 2005;115:358–363
  46. Matsui EC, Wood RA, Rand C, Kanchanaraksa S, Swartz L, Eggleston PA. Mouse allergen exposure and mouse skin test sensitivity in suburban, middle-class children with asthma. J Allergy Clin Immunol. 2004;113:910–915
  47. Park A, Edwards M, Donaldson M, Ghatei M, Meeran K. Lesson of the week: interfering antibodies affecting immunoassays in woman with pet rabbits. BMJ. 2003;326:541–542
  48. Platts-Mills TA, Satinover SM, Naccara L, Litonjua AA, Phipatanakul W, Carter MC, et al. Prevalence and titer of IgE antibodies to mouse allergens. J Allergy Clin Immunol. 2007;120:1058–1064
  49. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358:1109–1117
  50. Zanotti KM, Rybicki LA, Kennedy AW, Belinson JL, Webster KD, Kulp B, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol. 2001;19:3126–3129
  51. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921–926

 The desensitization program at Dana Farber Cancer Institute and Brigham and Women's hospital is supported in part by Ovations for the Cure.

 Disclosure of potential conflict of interest: P. J. Brennan received research support from the National Institutes of Health. T Rodriguez Bouza received research support from Real Colegio Complutense. F. I. Hsu received research support from Dyax. D. E. Sloane previously served on the speakers' bureau for Genentech and Novartis. M. C. Castells served as a consultant for Schering-Plough and ICON, received research support from Ovations for the Cure, and served as an expert witness on adverse drug reactions and desensitizations.

PII: S0091-6749(09)01338-4

doi: 10.1016/j.jaci.2009.09.009

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1259-1266 , December 2009

Article Tools

* Image Usage & Resolution